Psilocybin-Research.comSearchable psilocybin and psilocin bibliometric database.
Email alerts

Application overview

Source-labeled psilocybin and psilocin literature for search, monitoring, export, and citation workflows.

How the research index is built

Eight research sources feed Psilocybin-Research.com PubMed, OpenAlex, Crossref, Europe PMC, ClinicalTrials.gov, PsyArXiv, bioRxiv, and medRxiv provide records that are reconciled into the central research index. psilocybin-research.com PubMed OpenAlex Crossref Europe PMC ClinicalTrials.gov PsyArXiv bioRxiv medRxiv
Source records are fetched, reconciled, and labeled before appearing in the live index. The original sources remain authoritative.

Research workflow

Search, filter, export, analyze, and monitor publications with source labels, publication status, citation links, alerts, API access, and a rights-safe SQLite download. Read about the methods and limitations. Explore the dataset and reuse guide or research trends by year.

CLINICAL TRIAL

A Phase 2a Safety and Feasibility Study Evaluating Psilocybin (TRP-8802) Administration in Concert With Psychotherapy in the Treatment of Binge Eating Disorder

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal
ClinicalTrials.gov
Date
2024-11-19
Registry status
Completed
Registered conditions
Binge Eating Disorder
Study registration
NCT05035927 · INTERVENTIONAL
Source
ClinicalTrials.gov
DOI
Unavailable
PubMed
Unavailable

Authors

TRYP Therapeutics
Watch author

Derived topics and classifications

psilocybin DepressionAnxietyAddictionEating DisordersPharmacologyClinical TrialCancer PatientsTreatment-Resistant DepressionSafety Clinical Trial

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10A Phase III, Multicentre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10S1 Appendix - Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trialFigshare · 2025-09-19A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive DisorderClinicalTrials.gov · 2025-08-19Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness (PDR-Study)ClinicalTrials.gov · 2025-05-28A 24-Week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Clinical Trial to Evaluate Efficacy and Safety of Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD)ClinicalTrials.gov · 2024-08-15Effect of MDMA-assisted therapy on mood and anxiety symptoms in advanced-stage cancer (EMMAC): study protocol for a double-blind, randomised controlled trial.Trials · 2024-05-21Psilocybin for alcohol use disorder: Rationale and design considerations for a randomized controlled trial.Contemporary clinical trials · 2022-12-01